阿司匹林在房颤抗凝治疗中的弱化  

The limitations of aspirin for anticoagulation in atrial fibrillation

作　　者：从毅 金洪竹 高鸿慈[3] 文齐[3] 

机构地区：[1]武汉科技大学附属天佑医院急诊科,武汉430000 [2]武汉市汉口医院泌外甲胸科,武汉430000 [3]湖北中医药大学,武汉430065

出　　处：《广州医药》2015年第6期90-92,共3页Guangzhou Medical Journal

摘　　要：目的研讨阿司匹林广泛用于高危血栓、栓塞抗凝的预防治疗应用。方法查阅参考文献,结合临床实践,新口服抗凝药疗效终点卒中和体循环栓塞方面为基准。结果界於CHADS2和CHA2DS2-VASc评分所涵盖的风险和差异因素,后期华法林与新口服抗凝药可能取舍或并存。结论在危险分层,卒中抗拴防凝治疗中,我国房颤患者不建议继续服用阿司匹林。Objective To Study and discuss the applications for prevention and treatment of high risky thrombosis and embolism anticoagulation of Aspirin. Methods Combining literature consultation and clinical practice,making stroke and general circulation embolism of oral anticoagulant curative effect terminal point as the base. Results According to the risky and different factors covered by CHADS2 and CHA2DS2-VASc in the later stage,warfarin and the new oral anticoagulant can be taken together or abandon one of them. Conclusion In the risky factors classification and stroke anticoagulant therapy,we suggest that the atrial fibrillation patients should not take Aspirin.

关 键 词：阿司匹林 心房颤动 抗凝治疗 

分 类 号：R541.75[医药卫生—心血管疾病]